Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/20/16
End: 10/30/17
Due: 10/30/18
Phase: N/A
Priority: Normal
Start: 08/31/12
End: 06/30/18
Due: 06/30/19
Phase: N/A
Priority: Normal
Start: 04/25/17
End: 01/22/18
Due: 01/22/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | NCT02847000 | Yogen Saunthararajah | user2@example.com | None | 2016-12-20 | 2017-10-30 | 2018-10-30 | - | - | 2025-07-14 |
| Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease | NCT01685515 | Yogen Saunthararajah | user2@example.com | None | 2012-08-31 | 2018-06-30 | 2019-06-30 | - | - | 2025-07-14 |
| p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies | NCT02846935 | Yogen Saunthararajah | user2@example.com | None | 2017-04-25 | 2018-01-22 | 2019-01-22 | - | - | 2025-07-14 |